Skip to main content

Table 1 Brief introduction to the features of SGLT2i

From: SGLT2i: beyond the glucose-lowering effect

Trade name

â‘ Empagliflozin â‘¡Canagliflozin â‘¢Dapagliflozin â‘£Ertugliflozin

Target organ

Proximal tubule of kidney

Favorable aspects

â‘ Lower blood glucose

â‘¡Lower blood pressure (reduce systolic BP by 2.46 mmHg and diastolic BP by 1.46 mmHg)

③Lower body weight (3 kg–4 kg reduction)

④Lower glycosylated hemoglobin (0.7%–1% reduction)

⑤Increase high-density lipoprotein (HDL) cholesterol, and decrease triglycerides.

â‘¥Reduce albuminuria

⑦Reduce uric acid (10%–15% reduction)

⑧Increase hematocrit (2–4% increase)

Unfavorable aspects

â‘ Urinary tract infection

â‘¡Genital fungal infection

â‘¢Ketoacidosis

â‘£Fracture

⑤Malignant tumor

â‘¥Hypotension

⑦Dehydration

⑧Hypoglycemia

⑨Lower limb amputation

  1. BP blood pressure